Thiosulfuric acid
As of the edition of 20 October 2026, Thiosulfuric acid is a small molecule: marketed, first approved in 1992 (US); no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Nithiodote
- First approved
- 14 February 1992 (US)
- Approvals on record
- 7 in 4 regions
- Holder of the most recent approval
- Norgine B.V.; 6 holders in all
- Registered trials
- 48, 10 stopped early
- Disease areas
- Cancer; Nutrition and metabolism; Digestive system; Lungs and airways; Nervous system; Ear, nose and throat
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Hope Biosciences holds a later exclusivity on its own new formulation or combination product, ending 2031; it does not protect the original drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 2 | 2 | 1 |
| Phase 1 | 10 | 3 | 2 | 3 |
| Phase 2 | 22 | 10 | 3 | 3 |
| Phase 3 | 8 | 3 | 3 | 2 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 48 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant | 1998 to now |
| United States Army Office Surgeon General | Acquired holder | 2003 to now |
| Hope Biosciences | Later holder and Lead sponsor of trials | 2012 to now |
| Fennec Pharmaceuticals | Later holder | 2022 to now |